Initial dual oral therapy versus monotherapy for PAH with cardiovascular comorbidities
Official title: Comparison of Initial Dual Oral COMbination Therapy to MOnotherapy in Pulmonary Arterial Hypertension With Cardiovascular comorbiDITIES
Run by Assistance Publique - Hôpitaux de Paris · NCT07245680 · Data updated 2026-11-12
This trial will test whether starting both tadalafil and ambrisentan together works better than tadalafil alone for people newly diagnosed with pulmonary arterial hypertension who have at least two heart or vascular health problems.
Quick facts
| Phase | Phase 3 |
|---|---|
| Study type | Interventional |
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 186 (estimated) |
| Sponsor | Assistance Publique - Hôpitaux de Paris Academic / other |
| Locations | 1 site (Le Kremlin-Bicêtre) |
| Status | Recruiting |
| Started | April 28, 2026 |
| Main results expected | February 14, 2029 |
| Study ends | February 14, 2029 |
| Registry record updated | May 13, 2026 |
| Trial ID | NCT07245680 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are newly diagnosed, treatment-naïve group 1 PAH patients confirmed by right heart catheterization within six months who have at least two cardiovascular comorbidities such as hypertension, diabetes, obesity, coronary artery disease, or atrial fibrillation.
✕Probably not a fit
Patients with significant left heart disease, a positive vasoreactivity test, prior PAH therapy, or contraindications to endothelin receptor antagonists or PDE-5 inhibitors are unlikely to benefit from participation.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
The COMMODITIES trial randomizes newly diagnosed, treatment-naïve group 1 PAH patients with at least two cardiovascular comorbidities to receive either tadalafil plus ambrisentan or tadalafil plus placebo in a 1:1 open-label design. Eligibility requires confirmation by right heart catheterization and a negative vasoreactivity test. The primary outcome is the proportion of patients who reach a low- or intermediate-low risk profile by a noninvasive four-strata method after six months. A total of 186 participants will be followed over a planned 37-month study period to capture safety and short-term risk profile changes.
Why it matters
Potential benefit: If successful, the trial could show that initial combination oral therapy helps more high-risk PAH patients with cardiovascular comorbidities achieve a lower risk profile at six months, informing treatment guidelines.
How similar studies have gone: Previous trials such as AMBITION demonstrated benefit of initial ambrisentan plus tadalafil in PAH populations without major comorbidities, but patients with multiple cardiovascular comorbidities were often excluded, so this trial addresses that gap.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Initial PAH diagnosis \< 6 months preceding randomisation * Negative vasoreactivity test * Treatment-naïve PAH (group 1): idiopathic, heritable, associated with drugs and toxin, associated with connective tissue disease, HIV infection or systemic-to-pulmonary congenital shunt corrected for more than one year * Meet all of the following hemodynamic criteria by means of a RHC prior to screening: * mPAP≥25 mmHg and * PAWP\<15 mmHg and * with PVR≥3 WU • Presence of at least two of the following criteria, as listed in the European pulmonary hypertension guidelines: * History of essential hypertension * Diabetes mellitus (any type) * Obesity (defined by a BMI ≥30 kg/m2) * Coronary heart disease (established by any of the following: history of myocardial infarction, history of percutaneous coronary intervention, angiographic evidence of coronary artery disease (\>50% stenosis in ≥1 vessel), positive ST, previous coronary artery bypass graft, stable angina) * Participant able to understand the study procedures * For women of childbearing potential (WOCBP), effective form of contraception\* from screening up to 1 month following discontinuation of the last study treatment * Affiliation to the french social security regime * Signed written informed consent Exclusion Criteria: * Porto-pulmonary hypertension * Uncorrected systemic-to-pulmonary congenital shunt * Evidence of thromboembolic disease assessed by ventilation perfusion (V/Q) lung scan or CT pulmonary angiography * Patients listed for lung or heart-lung transplantation at time of screening * Patients on any PAH-specific drug therapy at any time preceding randomisation * Known moderate-to-severe restrictive lung disease (i.e., total lung capacity \< 60% of predicted value) or obstructive lung disease (i.e., forced expiratory volume in one second \[FEV1\] \< 60% of predicted, with FEV1 / forced vital capacity \< 65%) or known significant chronic lung disease diagnosed by chest imaging (e.g., interstitial lung disease, emphysema). * Known or suspected pulmonary veno-occlusive disease (PVOD) * Severe renal insufficiency (creatinine clearance \< 30 mL/min) * Documented severe hepatic impairment (with or without cirrhosis) according to National Cancer Institute organ dysfunction working group criteria, defined as total bilirubin \> 3 x ULN or serum AST and/or ALT \> 3xULN (assessed by local laboratory at screening) and/or Child-Pugh Class C. * Haemoglobin \< 10 g/dL * Patient under guardianship curatorship, deprived of liberty * Pregnant women, or breast-feeding women * Treatment with other PDE-5i for erectile dysfunction * Ongoing or planned treatment with nitrates and/or doxazosin. * Ongoing or planned treatment with riociguat * Treatment with strong inducers of CYP3A4 (e.g., carbamazepine, rifampin, rifampicin, rifabutin, rifapentin, phenobarbital, phenytoin, and St. John's wort) ≤28 days preceding randomisation
Where it's running
-
Hôpital Bicêtre -Service de pneumologie et soins intensifs respiratoires
Le Kremlin-Bicêtre, France Recruiting
Study contacts
- Study coordinator: Laurent SAVALE,, MD, PhD
- Email: laurent.savale@aphp.fr
- Phone: +33 1 45 21 79 08
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Cardiovascular Risk in Thai MASLD Patients: Coronary Calcium Scores
This study tests how well common cardiovascular risk tools align with coronary calcium scores in Thai adults with MASLD who have no heart symptoms.
-
Sleep problems in PAH patients: how sleep breathing relates to PAH outcomes
This study tests how sleep-disordered breathing and nocturnal oxygen changes relate to outcomes in adults with pulmonary arterial hypertension.
-
Understanding aldosterone in hypertension among Kaiser Permanente members
This is an observational program to see how aldosterone relates to high blood pressure in adults with hypertension, using data from Kaiser Permanente members in Northern California.
-
Impact of ambient air vs nasal liquid oxygen on exercise performance in pulmonary vascular disease
This study tests whether using nasal liquid oxygen during a 6-minute walk test changes how far patients with PAH or CTEPH can walk compared to breathing room air.
-
Liquid oxygen vs ambient air during a 6-minute walk in people with pulmonary vascular disease
This study tests whether walking with liquid oxygen at about 4 L/min helps or hinders distance walked compared with walking on room air in adults with PAH or CTEPH living in Switzerland.
-
Treprostinil inhalation powder for PAH patients switching from selexipag
This study tests whether inhaled treprostinil (LIQ861) is safe and tolerable for adults with PAH who are moving from oral selexipag to inhaled therapy.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.